Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
City of Hope Medical Center
150 participants
Jan 1, 2006
OBSERVATIONAL
Conditions
Summary
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Esophagectomy
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06476067